WO2010085542A3 - Biomarkers related to age-related macular degeneration (amd) - Google Patents

Biomarkers related to age-related macular degeneration (amd) Download PDF

Info

Publication number
WO2010085542A3
WO2010085542A3 PCT/US2010/021615 US2010021615W WO2010085542A3 WO 2010085542 A3 WO2010085542 A3 WO 2010085542A3 US 2010021615 W US2010021615 W US 2010021615W WO 2010085542 A3 WO2010085542 A3 WO 2010085542A3
Authority
WO
WIPO (PCT)
Prior art keywords
amd
age
macular degeneration
biomarkers
related macular
Prior art date
Application number
PCT/US2010/021615
Other languages
French (fr)
Other versions
WO2010085542A2 (en
Inventor
Martin Neuner-Jehle
Baldo Scassellati-Sforzolini
Thaddeus Dryja
Charles Paulding
Steven Lewitzky
Yunsheng He
Joanne Meyer
Lindsay Farrer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2010085542A2 publication Critical patent/WO2010085542A2/en
Publication of WO2010085542A3 publication Critical patent/WO2010085542A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of determining the therapeutic outcome of treating an AMD patient with an AMD therapeutic agent is provided. The method includes obtaining a sample from the patient, and analyzing the sample to determine the existence of one or more biomarkers associated with an improved response to treatment with the AMD therapeutic agent.
PCT/US2010/021615 2009-01-23 2010-01-21 Biomarkers related to age-related macular degeneration (amd) WO2010085542A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14685809P 2009-01-23 2009-01-23
US61/146,858 2009-01-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/138,233 A-371-Of-International US20120024196A1 (en) 2009-01-22 2010-01-21 Tailored geopolymer composite binders for cement and concrete applications
US14/960,770 Division US9834479B2 (en) 2009-01-22 2015-12-07 Tailored geopolymer composite binders for cement and concrete applications

Publications (2)

Publication Number Publication Date
WO2010085542A2 WO2010085542A2 (en) 2010-07-29
WO2010085542A3 true WO2010085542A3 (en) 2010-09-16

Family

ID=42125497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/021615 WO2010085542A2 (en) 2009-01-23 2010-01-21 Biomarkers related to age-related macular degeneration (amd)

Country Status (1)

Country Link
WO (1) WO2010085542A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
KR20130130732A (en) * 2010-11-01 2013-12-02 제넨테크, 인크. Predicting progression to advanced age-related macular degeneration using a polygenic score
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
US9896728B2 (en) * 2013-01-29 2018-02-20 Arcticrx Ltd. Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD)
WO2014143638A1 (en) 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
CN107318267B (en) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 Compositions and methods for treating complement-associated disorders
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
EA201692109A1 (en) 2014-05-01 2017-03-31 Дженентек, Инк. OPTIONS OF ANTIBODIES TO FACTOR D AND THEIR APPLICATION
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN104894261B (en) * 2015-06-02 2020-02-14 北京医院 Kit for predicting curative effect of ranibizumab on treatment of age-related macular degeneration
CN104878105B (en) * 2015-06-02 2017-10-31 北京医院 It is a kind of to predict the reagent that Lucentis treats AMD curative effect
CN108289951A (en) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 Anti- factor D antibody and conjugate
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN108712911A (en) 2015-12-30 2018-10-26 科达制药股份有限公司 Antibody and its conjugate
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096737A2 (en) * 2005-03-07 2006-09-14 The Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780233A (en) 1996-06-06 1998-07-14 Wisconsin Alumni Research Foundation Artificial mismatch hybridization

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096737A2 (en) * 2005-03-07 2006-09-14 The Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDREW LOTERY ET AL: "Progress in defining the molecular biology of age related macular degeneration", HUMAN GENETICS, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/S00439-007-0406-3, vol. 122, no. 3-4, 21 July 2007 (2007-07-21), pages 219 - 236, XP019563961, ISSN: 1432-1203 *
BRANTLEY ET AL: "Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US LNKD- DOI:10.1016/J.OPHTHA.2007.09.008, vol. 114, no. 12, 27 November 2007 (2007-11-27), pages 2168 - 2173, XP022382053, ISSN: 0161-6420 *
DE CORDOBA SANTIAGO RODRIGUEZ ET AL: "The human complement factor H: functional roles, genetic variations and disease associations", MOLECULAR IMMUNOLOGY, PERGAMON, GB LNKD- DOI:10.1016/J.MOLIMM.2004.02.005, vol. 41, no. 4, 3 April 2004 (2004-04-03), pages 355 - 367, XP002391912, ISSN: 0161-5890 *
GEHRS K M ET AL: "Age-related macular degeneration - Emerging pathogenetic and therapeutic concepts", ANNALS OF MEDICINE, TAYLOR & FRANCIS A B, SE LNKD- DOI:10.1080/07853890600946724, vol. 38, no. 7, 1 November 2006 (2006-11-01), pages 450 - 471, XP009105015, ISSN: 0785-3890 *
JAGER R D ET AL: "Age-related macular degeneration", NEW ENGLAND JOURNAL OF MEDICINE 20080612 US LNKD- DOI:10.1056/NEJMRA0801537, vol. 358, no. 24, 12 June 2008 (2008-06-12), pages 2606 - 2617+2544, XP002581541, ISSN: 0028-4793 *
LEE A Y ET AL: "Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab", BRITISH JOURNAL OF OPHTHALMOLOGY, LONDON, GB, vol. 93, no. 5, 17 December 2008 (2008-12-17), pages 610 - 613, XP009129122, ISSN: 0007-1161 *
NCBI-DBSNP: "rs1061170", 25 May 2006 (2006-05-25), XP002427182, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/SNP> [retrieved on 20100507] *

Also Published As

Publication number Publication date
WO2010085542A2 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2010085542A3 (en) Biomarkers related to age-related macular degeneration (amd)
EP2259069A4 (en) Blood coagulation analyzer, method of analyzing blood coagulation and computer program
EP2375244A4 (en) Blood coagulation system analyzer, and blood coagulation system analysis method and program
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
EP2179037A4 (en) Methods for diagnosis, prognosis and methods of treatment
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2010091049A3 (en) Diagnosis and treatment of cancer
EP2250282A4 (en) Methods of diagnosing and treating parp-mediated diseases
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2012054588A3 (en) Conduit-containing devices and methods for analyte processing and detection
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
WO2008013893A3 (en) Diagnosis and treatment of age related macular degeneration
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
WO2009142744A3 (en) Predicting hemostatic risk; dependence on plasma composition
WO2012126542A3 (en) Biomarkers and methods for the prognosis of glioblastoma
ZA201107242B (en) Device and method for the verification and quantitative analysis of analytes, particularly mycotoxins
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
WO2009140556A3 (en) Genotype and expression analysis for use in predicting outcome and therapy selection
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2009089521A3 (en) Predictors for evaluating response to cancer therapy
WO2008115710A3 (en) Biomarkers for cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10701772

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10701772

Country of ref document: EP

Kind code of ref document: A2